Mironid is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signaling proteins.
At Nanovery, their cutting-edge DNA nanorobots are revolutionising the biotechnology landscape. As pioneers in nucleic acid nanorobotics (NANs), our platform is the first to provide comprehensive solutions for RNA therapeutic analysis and biomarker quantification. This innovation elevates research precision and simplifies testing protocols.
Their mission is to make the testing processes as simple as possible to drive advancements in biotech research. Nanovery's NANs technology is not just part of biotechnology's future; it is actively shaping it, ensuring their partners stay at the forefront of innovation.
Our vision is to employ new dual-acting retinoic acid receptor modulators (RAR-M) as the basis for developing a new rational effective treatment approach for ALS and meet that unmet need. In the longer term, we see a great opportunity to use our IP from the ALS arena to move on to target the wider range of neurodegenerative diseases.
The NIHR (National Institute for Health Research) funds, enables and delivers world-class health and care research that transforms people’s lives, advances science globally and benefits the UK economy.
The NIHR:
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
Nucleome is an immunology company tackling the root causes of disease through a revolutionary new approach to solving human genetics. Nucleome has a deep molecular understanding of the function and importance of the non-coding genome and how variation within it causes disease. The Company has created transformative 3D genomics technology to link disease-associated genetic variants with the genes they dysregulate in disease. At the core of this, is the ability to read 3D interactions in the non-coding genome with a precision and scale that is unique in both industry and academia.
Nucleome is the first company to build at scale a rich data atlas of immune system dysregulation identified from human disease genetics, allowing it to elucidate the mechanistic basis of disease, identify hundreds of novel targets and group patients by their common, mechanistic disease drivers. The Company is building a pipeline of genetically identified therapeutics to restore health in inflammatory diseases, with lead programme, NTP464, in pre-clinical development.
Nucleome is backed by a world-class syndicate of investors: M Ventures, the venture capital arm of Merck KGaA; Johnson and Johnson Innovation – JJDC, Inc. (“JJDC”); Pfizer Ventures; British Business Bank and founding investor Oxford Science Enterprises. Visit the website to find out more at: www.nucleome.com
OBN is the not-for-profit Membership organisation supporting and bringing together the UK’s life sciences companies, corporate partners and investors. Our 400-plus Member companies are located across the Golden Triangle and beyond to Manchester, Nottingham, the Midlands, South Coast and Scotland, benefiting from our networking, partnering, purchasing, training, advising and advocacy activities.
OFX is a global company that provides international money transfers at competitive exchange rates for both businesses and consumers. It offers fee-free transactions, 24/7 customer service and rapid round-the-clock transfers thanks to its unique ‘follow-the-sun’ service model.
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. With a partnership led approach, Oncimmune is evolving and leveraging its technology with global pharmaceutical and biotechnology companies, early-stage start-ups, leading academic groups, and not-for-profit companies.
ImmunoINSIGHTS is Oncimmune’s service to the life science industry, built off the company’s proprietary autoantibody profiling technology. Underpinned by Oncimmune’s proprietary high throughput immunogenic protein library, one of the largest in the world, covering more than 95% of known human antigens, the technology can be utilised for profiling autoantibodies in patients receiving or about to receive treatment. This unique combination of Oncimmune’s core technology and understanding of the immune system enables life-science organisations to optimise drug development, leading to more effective, targeted, as well as safer treatments for patients.
One Nucleus is a Cambridge/London Life Science membership organisation. We support Europe’s largest Life Science cluster encompassing the London-Cambridge-East of England region via knowledge transfer, connectivity, inward investment and growth.
Onyx Scientific is a small molecule CDMO specialising in process R&D, non-GMP scale up and GMP manufacture for clinical trials and commercial. Good chemistry is at the core of everything we do. From our facilities in the UK and US, our teams of chemists will guide your small molecule API through development and manufacturing from the moment a lead molecule is identified, taking it into Phase I studies and right through to commercial manufacture.
